Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02837991 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
A Phase 1 study, sponsored by Celldex Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02837991 is a Phase 1 study that was terminated before completion, run by Celldex Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT02837991, a Phase 1 study, was terminated before completion, sponsored by Celldex Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a study to determine the safety of CDX-014 and effectiveness (how well the drug works).
Interventions
- DRUG CDX-014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-06 |
| Est. Completion | 2018-11-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02837991
The ClinicalTrials.gov registry entry for NCT02837991 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CDX-014 is the first listed.
NCT02837991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02837991 about?
NCT02837991 is a clinical study titled "A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma". This is a study to determine the safety of CDX-014 and effectiveness (how well the drug works).
What is the current status of trial NCT02837991?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-06. Estimated completion is 2018-11-16.
What interventions are being tested in trial NCT02837991?
The interventions under investigation include: CDX-014 (DRUG).
Who is sponsoring clinical trial NCT02837991?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.